We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Guidelines Designed to Help Diagnose Chronic Diarrhea

By LabMedica International staff writers
Posted on 30 Sep 2019
Print article
A newly published official guideline for diagnosing chronic watery diarrhea was established to aid clinicians in choosing appropriate laboratory tests to exclude other diagnoses in the setting of suspected functional diarrhea or diarrhea-predominant irritable bowel syndrome (IBS-D).

The guidelines, “Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D)”, which will be in force for five years, were developed by the American Gastroenterological Association Clinical Practice Guideline Committee and were approved by the association’s governing board.

These guidelines apply to the evaluation of immunocompetent adult patients with “watery” diarrhea of at least four weeks duration. This would exclude those patients with bloody diarrhea; diarrhea with signs of fat malabsorption; presentations with alarm features, such as weight loss, anemia and hypoalbuminemia; those patients with a family history of inflammatory bowel disease (IBD), colon cancer, or celiac disease; and those with a travel history to regions with recognized specific diarrhea-related pathogens.

Some key recommendations include: (1) testing for celiac disease (an important cause of chronic diarrhea) with IgA tissue transglutaminase and a second test to detect celiac disease in the setting of IgA deficiency; (2) testing for Giardia, a common cause of watery diarrhea that can be readily treated; (3) testing for bile acid diarrhea, which may be due to excess production or decreased absorption of bile acids, which then reach the colon and can cause watery diarrhea. The guideline suggested not using erythrocyte sedimentation rate or C-reactive protein to screen for IBD, and not testing for ova and parasites other than Giardia.

“When managing patients with chronic watery diarrhea, it is important for health care providers to determine whether it is being caused by organic disease or a functional disorder, such as functional diarrhea or irritable bowel syndrome with diarrhea,” said first author Dr. Walter Smalley, professor of medicine at Vanderbilt University School of Medicine (Nashville, TN, USA). “Both functional diarrhea and IBS-D are clinical diagnoses with no defining laboratory tests. A workup to exclude all organic disease is impractical, expensive, and potentially dangerous to patients if false-positive tests result in further invasive testing. The AGA guideline on evaluation of chronic diarrhea is intended to reduce practice variation and promote high-quality and high-value care for this patient population.”

The guidelines were published in the September 2019 issue of the journal Gastroenterology.

Related Links:
American Gastroenterological Association
Vanderbilt University School of Medicine

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.